High-density lipoprotein metabolism and endothelial function

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 2, 2010, Pages 166-170

  Lowenstein, Charles J ^a   Cameron, Scott J ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Apolipoprotein A I; Hyperlipidemia; Inflammation; Macrophage; Nitric oxide

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG TARGETING; DYSLIPIDEMIA; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; LIVER; MACROPHAGE; NONHUMAN; REVIEW; THROMBOSIS;

ANIMALS; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; LIPID METABOLISM; LIPOPROTEINS, HDL; MODELS, BIOLOGICAL; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; THROMBOSIS; VASCULITIS;

EID: 77749325120     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32833727ee     Document Type: Review

References (54)

1. Rhoads GG, Gulbrandsen CL, Kagan A. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med 1976; 294:293-298.
2. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 1977; 62:707-714.
3. Simons K, Ikonen E. How cells handle cholesterol. Science 2000; 290: 1721-1726.
4. Tall AR, Costet P, Wang N. Regulation and mechanisms of macrophage cholesterol efflux. J Clin Invest 2002; 110:899-904.
5. Choudhury RP, Rong JX, Trogan E, et al. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol 2004; 24:1904-1909.
6. Shaul PW,Mineo C. HDL action on the vascular wall: is the answer NO? J Clin Invest 2004; 113:509-513.
7. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005; 4:193-205.
8. Navab M, Anantharamaiah GM, Fogelman AM. The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med 2005; 15:158-161.
9. Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res 2004; 95:764-772.
10. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL: guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006; 3:144-153.
11. Barter PJ, Puranik R, Rye KA. New insights into the role of HDL as an antiinflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep 2007; 9:493-498.
12. Glomset JA. The metabolic role of lecithin: cholesterol acyltransferase - perspectives from pathology. Adv Lipid Res 1973; 11:1-65.
13. Ishida T, Choi S, Kundu RK, et al. Endothelial lipase is a major determinant of HDL level. J Clin Invest 2003; 111:347-355.
14. Jin W, Millar JS, Broedl U, et al. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest 2003; 111:357-362.
15. Glass C, Pittman RC, Weinstein DB, Steinberg D. Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad. Proc Natl Acad Sci U S A 1983; 80:5435-5439.
16. Acton S, Rigotti A, Landschulz KT, et al. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271:518-520.
17. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122.
18. Zeiher AM, Schachlinger V, Hohnloser SH, et al. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 1994; 89:2525-2532.
19. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105:1399-1402.
20. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003; 107:2944-2948.
21. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001; 7:853-857.
22. Nofer JR, van der Giet M, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004; 113:569-581.
23. Igarashi J, Thatte HS, Prabhakar P, et al. Calcium-independent activation of endothelial nitric oxide synthase by ceramide. Proc Natl Acad Sci U S A 1999; 96:12583-12588. (Pubitemid 29513545)
24. Gong M, Wilson M, Kelly T, et al. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J Clin Invest 2003; 111:1579-1587.
25. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7:678-689.
26. Cockerill GW, Saklatvala J, Ridley SH, et al. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase- 2. Arterioscler Thromb Vasc Biol 1999; 19:910-917.
27. Cockerill GW, Huehns TY, Weerasinghe A, et al. Elevation of plasma highdensity lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001; 103:108-112.
28. Cockerill GW, Rye KA, Gamble JR, et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15:1987-1994.
29. Ashby DT, Rye KA, Clay MA, et al. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18:1450-1455.
30. Dansky HM, Charlton SA, Barlow CB, et al. Apo A-I inhibits foam cell formation in Apo E-deficient mice after monocyte adherence to endothelium. J Clin Invest 1999; 104:31-39.
31. Park SH, Park JH, Kang JS, Kang YH. Involvement of transcription factors in plasma HDL protection against TNF-alpha-induced vascular cell adhesion molecule-1 expression. Int J Biochem Cell Biol 2003; 35:168-182.
32. Kimura T, Tomura H, Mogi C, et al. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem 2006; 281:37457-37467.
33. Hessler JR, Robertson AL Jr, Chisolm GM 3rd. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979; 32:213-229.
34. Shih DM, Gu L, Hama S, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97:1630-1639.
35. Shih DM,GuL, Xia YR, et al. Mice lacking serumparaoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394:284-287.
36. Tward A, Xia YR, Wang XP, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106:484-490.
37. Troughton JA, Woodside JV, Yarnell JW, et al. Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: the PRIME study. Atherosclerosis 2008; 197:556-563.
38. Regieli JJ, Jukema JW, Doevendans PA, et al. Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoproteinbound antioxidant in secondary prevention. J Am Coll Cardiol 2009; 54:1238-1245.
39. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299:1265-1276.
40. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98:1352-1364.
41. Deguchi H, Pecheniuk NM, Elias DJ, et al. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005; 112:893-899.
42. Eichinger S, Pecheniuk NM, Hron G, et al. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation 2007; 115:1609-1614. (Pubitemid 46648646)
43. Fleisher LN, Tall AR, Witte LD, et al. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 1982; 257:6653-6655.
44. Spector AA, Scanu AM, Kaduce TL, et al. Effect of human plasma lipoproteins on prostacyclin production by cultured endothelial cells. J Lipid Res 1985; 26:288-297.
45. Symons JD. Longitudinal and cross-sectional studies of the relationship between 6-keto PGF1 alpha and high density lipoproteins. Prostaglandins Leukot Essent Fatty Acids 1990; 39:159-165.
46. Griffin JH, Kojima K, Banka CL, et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103:219-227.
47. Naqvi TZ, Shah PK, Ivey PA, et al. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol 1999; 84:1011-1017.
48. Beitz J, Kuklinski B, Taube C, Mest HJ. Influence of a plasma fraction of human blood, rich in high density lipoprotein, on in vitro formation of prostaglandin I2 (PGI2) and thromboxane A2 (TXA2). Prostaglandins Leukot Essent Fatty Acids 1989; 35:37-39.
49. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96:2758-2767.
50. Van Lenten BJ, Wagner AC, Nayak DP, et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 2001; 103:2283-2288.
51. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114:529-541.
52. Undurti A, Huang Y, Lupica JA, et al. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem 2009; 284:30825-30835.
53. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117:746-756.
54. Green PS, Vaisar T, Pennathur S, et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 2008; 118: 1259-1267.